We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of the oral hypoglycaemic sulphonylurea glibenclamide, a blocker of ATP-sensitive potassium channels, on walking distance in patients with intermittent claudication.
- Authors
Mortensen, U. M.; Nielsen-Kudsk, J. E.; Sondergaard, H. M.; Jakobsen, P.; Jensen, B. S.; Schmitz, O.; Nielsen, T. T.
- Abstract
Aims The oral hypoglycaemic sulphonylurea glibenclamide stimulates endogenous insulin secretion through blockade of ATP-sensitive potassium (KATP) channels on pancreatic β cells, but also blocks cardiovascular KATP channels, leading to increased peripheral vascular resistance and reduced peripheral blood flow in non-diabetic subjects. Therefore, this study examined whether a single oral dose of glibenclamide adversely affected the pain-free or maximal walking distance in patients with intermittent claudication. Methods In a double-blind, randomized crossover study, 12 non-diabetic patients with intermittent claudication were given a single oral dose of glibenclamide (5.25 mg) or placebo separated by a washout period of 1 week. A treadmill test was carried out 180 min after glibenclamide/placebo intake for determination of pain-free and maximal walking distance. Plasma glucose concentrations were kept constant by an euglycemic clamp. Changes in ankle/brachial blood pressure index (ABI), serum insulin, and serum glibenclamide were also assessed. Results The pain-free walking distance was 62.8 ± 9.8 metres (mean ± sem) after glibenclamide and 52.6 ± 5.9 metres after placebo ( P = 0.52). The maximal walking distance was 142.7 ± 18.7 metres after glibenclamide and 132.6 ± 16.6 metres after placebo ( P = 0.23). The ABI was not significantly changed by glibenclamide compared with placebo. Serum glibenclamide was 0.51 ± 0.08 µm 180 min after administration of the drug. Glibenclamide produced an 8-fold increase in circulating insulin compared with placebo ( P < 0.001). Conclusions Glibenclamide given as a single oral dose commonly used in glucose-lowering drug therapy does not reduce pain-free or maximal walking distance in non-diabetic patients with intermittent claudication.
- Subjects
HYPOGLYCEMIC sulfonylureas; GLIBENCLAMIDE; HYPOGLYCEMIC agents; PEOPLE with diabetes; INSULIN; GLUCOSE
- Publication
Diabetic Medicine, 2006, Vol 23, Issue 3, p327
- ISSN
0742-3071
- Publication type
Article
- DOI
10.1111/j.1464-5491.2006.01797.x